MedTrace Logo

The Performance / Safety of the Celsite® Venous Access Ports

NCT05572112 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-10-07

No results posted yet for this study

Summary

The Celsite® Venous Access Ports System are intended to be used for repeated intravenous administration of, for example, chemotherapy, antibiotic and antiviral drugs, total parenteral nutrition, blood sampling or transfusion.

The objective is to assess the device's safety to deliver medication over the time in regard to the rate of adverse events related to the Celsite® access ports written in the IFU.

Conditions

  • The Performance / Safety of the Celsite® Venous Access Ports

Interventions

DEVICE

Venous access port implantation

Venous access port implantation

Sponsors & Collaborators

  • B.Braun Médical - CoE Chasseneuil

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-15
Primary Completion
2023-01-30
Completion
2025-01-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05572112 on ClinicalTrials.gov